Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03526263 · ClinicalTrials.gov registry record · NA
Endoscopic Gastric Mucosal Devitalization (GMD) as a Primary Obesity Therapy
A NA study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- NA
- Development phase
- 6
- Enrollment target
NCT03526263: Completed NA study, sponsored by Johns Hopkins University.
NCT03526263 is a NA study that has completed, run by Johns Hopkins University. The registered enrollment target is 6 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03526263, a NA study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
Study Summary
Rapid metabolic improvements seen with sleeve gastrectomy are likely a result of changes in gastric origin. The gastric mucosa is an endocrine organ that regulates satiation pathways and is a complex regulator of food intake as well as lipid and glucose metabolism. This study aims to assess the efficacy and safety of endoscopic selective gastric mucosal devitalization (GMD) for the management of obesity and its related comorbidities.
Primary Outcome
Identify the optimal color of the tissue indicating that the gastric mucosa has been sufficiently treated such that selective mucosal devitalization has occurred (as determined by a pathologist examining the samples)
Interventions
- PROCEDURE Gastric mucosal devitalization
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2018-06-07 |
| Est. Completion | 2018-11-29 |
| Phase | NA |
What the finished NCT03526263 record still lists
NCT03526263 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which Gastric mucosal devitalization is the first listed.
NCT03526263 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03526263 about?
NCT03526263 is a clinical study titled "Endoscopic Gastric Mucosal Devitalization (GMD) as a Primary Obesity Therapy". Rapid metabolic improvements seen with sleeve gastrectomy are likely a result of changes in gastric origin. The gastric mucosa is an endocrine organ that regulates satiation pathways and is a complex regulator of food intake as well as lipid and glucose metabolism. This study aims to assess the effi...
What is the current status of trial NCT03526263?
This trial is currently completed. It is a NA study. The enrollment target is 6 participants. The study started on 2018-06-07. Estimated completion is 2018-11-29.
What interventions are being tested in trial NCT03526263?
The interventions under investigation include: Gastric mucosal devitalization (PROCEDURE).
Who is sponsoring clinical trial NCT03526263?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03526263's enrollment target sits among peer trials
6 1983rd of 2000 higher than 13 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI